Test Price
200 AED✅ Home Collection Available
Cervical Screening Test (LBC & HPV Co-test) in Dubai | 200 AED | DHA Approved
Executive Summary & Core Metrics
Executive Summary: The combined liquid-based cytology (LBC) and high-risk HPV DNA detection (RT-PCR) delivers >99.9% sensitivity for clinically significant cervical lesions. Price: 200 AED. Turnaround: 2–3 working days. VIP mobile phlebotomy for home collection (8 AM–11 PM) with temperature-controlled cold-chain transport. Immediate insurance verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Cervical Screening Test integrates Liquid-Based Cytology (LBC) with High-Risk HPV DNA detection by real-time PCR to identify precancerous cellular changes and oncogenic HPV genotypes (16, 18, other high-risk) from a single endocervical specimen. This dual-method approach, aligned with DHA screening protocols, improves detection rates and reduces unnecessary repeat procedures.
The methodology uses ThinPrep®-equivalent liquid preservation, followed by automated slide preparation and interpretation by certified cytotechnologists. HPV testing is performed on the Cepheid GeneXpert® platform for rapid, genotype-specific results.
| Feature | Our DHA-Approved Test | Conventional Pap Smear Alone |
|---|---|---|
| Precision/Sensitivity | >99.9% for high‑grade lesions (LBC + HR‑HPV PCR) | ~60–80%; higher false‑negative rate |
| Methodology | Liquid‑Based Cytology (ThinPrep® equivalent) + RT‑PCR (Cepheid GeneXpert®) | Conventional Papanicolaou stain on glass slide |
| Turnaround Time | 2–3 working days | 5–10 working days |
| HPV Genotyping | Simultaneous high‑risk HPV (16,18, other hr) detection | Not included (requires separate test) |
| Sample Stability | LBC vial preserves cells; cold‑chain transport | Smear must be fixed immediately; prone to air‑drying |
| DHA & ISO Compliance | Full compliance; ISO 9001:2015 (INT/EGQ/2509DA/3139) | Often lacks cold‑chain rigor |
Physician Insight & Safety Protocols
Dr. Ajay Singh (DHA Registration ID: 36234132), General Practitioner, advises: “Cervical screening is a cornerstone of preventive women’s health. This combined test provides the highest sensitivity for early detection. Always discuss any abnormal results with your doctor for appropriate follow-up, which may include colposcopy. Continue all medications as prescribed unless your physician directs otherwise.”
Advisory: Medication Continuation
⚠️ Do not discontinue any prescribed medication without consulting your doctor. This screening test does not interfere with regular medications.
Patient Safety & Exclusion Criteria
Exclusion Criteria:
- Active heavy menstrual bleeding or vaginal hemorrhage.
- Known allergy to latex or collection brush materials.
- Severe cervical stenosis or recent cervical surgery (within 6 weeks).
- Pregnancy: Screening is safe in early pregnancy; after 12 weeks, consult your obstetrician.
- Emergency Red Flags: Severe pelvic pain, heavy bleeding, or signs of infection (fever, foul discharge) after specimen collection – seek immediate medical attention.
Patient FAQ & Clinical Guidance
1. What exactly does the Cervical Screening Test (LBC + HPV co-test) detect?
The test simultaneously screens for abnormal cervical cell changes and high-risk HPV DNA to detect precancerous lesions early. Combining LBC and RT-PCR achieves near-100% sensitivity for clinically significant disease.
2. How often should I have this combined screening according to DHA guidelines?
The DHA recommends cervical screening every 3–5 years for women aged 25–65, depending on risk factors. Women with prior abnormal results or immunosuppression may require more frequent screening – discuss with your gynaecologist.
3. Is the at-home sample collection safe, private, and DHA-approved?
Yes. Our DHA-licensed nurses follow strict aseptic technique and cold-chain protocol. The VIP mobile phlebotomy service operates daily 8 AM–11 PM, using the special LBC collection kit for maximum comfort and privacy.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This test is performed under DHA Facility License No. 1143. All personal data is processed in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your medical information is encrypted and used solely for diagnostic purposes with your explicit consent.
Clinical & Logistical Metadata
| Test Name | Cervical Screening Test (LBC + HPV Co-test) |
| Price (AED) | 200 |
| Turnaround Time | 2–3 working days |
| Sample Type / Matrix | Cervical cells (Liquid-Based Cytology) – endocervical brush preserved in ThinPrep® equivalent medium |
| Methodology Used | Liquid-Based Cytology + Real-Time PCR (Cepheid GeneXpert®) for high-risk HPV DNA |
| ICD-10-CM Code | Z12.4 (Encounter for screening for malignant neoplasm of cervix) |
| LOINC Code | 82499-5 (HPV DNA and cytology interpretation) |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians